Physician profile
Robert M Grohowski
NPI 1700857356
$8,338.87
in general payments reported to CMS, 2019-2025
36 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,724 · 2020: $393 · 2021: $962 · 2022: $1,699 · 2023: $1,964 · 2024: $283 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,560.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Artivion, INC. | $1,062.38 | 2019 | |
| Amgen INC. | $852.33 | 2019-2023 | Repatha |
| Novartis Pharmaceuticals Corporation | $760.74 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $735.50 | 2019-2023 | Xarelto |
| Kestra Medical Technology Services, INC. | $503.28 | 2023-2025 | Assure Wcd |
| Pfizer INC. | $470.61 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $438.30 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.96 | 2019-2024 | Jardiance |
| Cvrx, INC. | $339.39 | 2022-2025 | Barostim Neo System |
| Abbott Laboratories | $318.34 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $307.95 | 2019-2025 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $277.04 | 2019-2023 | Evkeeza, Praluent |
| Amarin Pharma, INC. | $259.96 | 2019-2022 | |
| Boston Scientific Corporation | $204.90 | 2021-2022 | |
| W. L. Gore & Associates, INC. | $187.55 | 2023 | Gore Excluder Aaa Endoprosthesis |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $136.88 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Irhythm Technologies, INC. | $136.34 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $130.92 | 2023-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $130.24 | 2019-2023 | Eliquis |
| Philips North America LLC | $109.00 | 2023-2025 | (Ck7) Extended Holter, Event, Extended Holter |
| Lexicon Pharmaceuticals, INC. | $80.35 | 2023 | Inpefa |
| Bayer Healthcare Pharmaceuticals INC. | $70.59 | 2023 | |
| Astellas Pharma US INC | $67.14 | 2019 | |
| Impulse Dynamics (USA) INC. | $66.10 | 2024 | Optimizer |
| Heartflow, INC. | $47.68 | 2023 | Ffrct |
| Esperion Therapeutics, INC. | $38.29 | 2022-2025 | Nexletol |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.77 | 2020-2025 | Lifevest |
| Novo Nordisk INC | $28.49 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $27.40 | 2023 | Onpattro |
| Daiichi Sankyo INC. | $24.38 | 2021 | |
| Medtronic, INC. | $22.86 | 2024 | Linq II |
| Cashflow Solutions, LLC | $17.74 | 2025 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Kiniksa Pharmaceuticals, LTD. | $17.56 | 2023 | Arcalyst |
| Medtronic Vascular, INC. | $15.98 | 2020 | |
| Preventice Services, LLC | $14.79 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Grohowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.